Is There a Gender Effect in Polycythemia Vera?

Overview

Journal Ann Hematol

Specialty Hematology

Date 2020 Oct 2

PMID 33006021

Citations 5

Authors

Francesca Palandri

Barbara Mora

Naseema Gangat

Lucia Catani

Affiliations

Soon will be listed here.

Abstract

In recent times, there has been a growing interest in understanding the impact of gender on disease biology and clinical outcomes in Philadelphia-negative chronic myeloproliferative neoplasms. Among those, polycythemia vera (PV) is characterized by increased thrombotic risk, systemic symptoms, and overall reduced survival. Here, we aim to summarize data on whether and to what extent female sex can affect PV biology and outcome. To this end, we will discuss the latest acquisitions in terms of pathogenesis, diagnosis, epidemiology, clinical presentation and symptoms burden, thrombotic risk and related treatment strategies, and prognosis in female patients affected by PV.

Citing Articles

Prognostic and Predictive Models in Myelofibrosis.

Mora B, Bucelli C, Cattaneo D, Bellani V, Versino F, Barbullushi K Curr Hematol Malig Rep. 2024; 19(5):223-235.

PMID: 39179882 PMC: 11416430. DOI: 10.1007/s11899-024-00739-6.

Polycythemia vera disease profile in an African population-experience from a tertiary facility in Ghana.

Gyabaah S, Ahmed E, Adu-Gyamfi A, Gyabaah F, Bonsu A, Addo A SAGE Open Med. 2023; 11:20503121231187747.

PMID: 37529706 PMC: 10387680. DOI: 10.1177/20503121231187747.

Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.

Mora B, Passamonti F Curr Hematol Malig Rep. 2022; 17(5):127-139.

PMID: 36048275 PMC: 9499895. DOI: 10.1007/s11899-022-00672-6.

Tipgomut C, Khuhapinant A, Wilson M, Poldee S, Heesom K, Metheetrairut C Sci Rep. 2021; 11(1):22483.

PMID: 34795367 PMC: 8602418. DOI: 10.1038/s41598-021-01877-0.

The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters.

Catani L, Cavo M, Palandri F Cells. 2021; 10(9).

PMID: 34571965 PMC: 8464728. DOI: 10.3390/cells10092316.

References

Pearson T, Messinezy M . The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma. 1996; 22 Suppl 1:87-93. View

Kralovics R, Teo S, Li S, Theocharides A, Buser A, Tichelli A . Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006; 108(4):1377-80. DOI: 10.1182/blood-2005-11-009605. View

Passamonti F . How to manage polycythemia vera. Leukemia. 2011; 26(5):870-4. DOI: 10.1038/leu.2011.334. View

Stein B, Rademaker A, Spivak J, Moliterno A . Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms. Thrombosis. 2011; 2011:874146. PMC: 3200304. DOI: 10.1155/2011/874146. View

Denninger M, Chait Y, Casadevall N, Hillaire S, Guillin M, Bezeaud A . Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000; 31(3):587-91. DOI: 10.1002/hep.510310307. View

Datta P, Rewers-Felkins K, Kallem R, Baker T, Hale T . Transfer of Low Dose Aspirin Into Human Milk. J Hum Lact. 2017; 33(2):296-299. DOI: 10.1177/0890334417695207. View

Gialeraki A, Valsami S, Pittaras T, Panayiotakopoulos G, Politou M . Oral Contraceptives and HRT Risk of Thrombosis. Clin Appl Thromb Hemost. 2017; 24(2):217-225. PMC: 6714678. DOI: 10.1177/1076029616683802. View

Cerquozzi S, Tefferi A . Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015; 5:e366. PMC: 4670948. DOI: 10.1038/bcj.2015.95. View

Tefferi A, Guglielmelli P, Larson D, Finke C, Wassie E, Pieri L . Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014; 124(16):2507-13. PMC: 4199952. DOI: 10.1182/blood-2014-05-579136. View

10.

Robinson S, Harrison C . How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy. Br J Haematol. 2020; 189(4):625-634. DOI: 10.1111/bjh.16453. View

11.

Alvarez-Larran A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernandez-Boluda J, Ferrer-Marin F . Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2011; 119(6):1363-9. DOI: 10.1182/blood-2011-10-387787. View

12.

Murphy W . The sex difference in haemoglobin levels in adults - mechanisms, causes, and consequences. Blood Rev. 2014; 28(2):41-7. DOI: 10.1016/j.blre.2013.12.003. View

13.

Jayasuriya N, Kjaergaard A, Pedersen K, Sorensen A, Bak M, Larsen M . Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people. Br J Haematol. 2019; 189(2):323-334. DOI: 10.1111/bjh.16321. View

14.

Silver R, Chow W, Orazi A, Arles S, Goldsmith S . Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2013; 122(11):1881-6. DOI: 10.1182/blood-2013-06-508416. View

15.

De Stefano V, Za T, Ciminello A, Betti S, Rossi E . Causes of adult splanchnic vein thrombosis in the mediterranean area. Mediterr J Hematol Infect Dis. 2012; 3(1):e2011063. PMC: 3248340. DOI: 10.4084/MJHID.2011.063. View

16.

Beauverd Y, Radia D, Cargo C, Knapper S, Drummond M, Pillai A . Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica. 2016; 101(5):e182-4. PMC: 5004380. DOI: 10.3324/haematol.2015.139691. View

17.

Alvarez-Larran A, Kerguelen A, Hernandez-Boluda J, Perez-Encinas M, Ferrer-Marin F, Barez A . Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016; 172(5):786-93. DOI: 10.1111/bjh.13886. View

18.

Tefferi A, Lavu S, Mudireddy M, Lasho T, Finke C, Gangat N . JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. Am J Hematol. 2017; 93(4):E93-E96. DOI: 10.1002/ajh.25017. View

19.

Cartwright R, Gurney K, Moorman A . Sex ratios and the risks of haematological malignancies. Br J Haematol. 2002; 118(4):1071-7. DOI: 10.1046/j.1365-2141.2002.03750.x. View

20.

Kiladjian J, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N . Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia. 2006; 20(6):1181-3. DOI: 10.1038/sj.leu.2404214. View